Fundraising FoxSolve Therapeutics
4 known investors
Find your way into Solve Therapeutics
Sign up to see every warm intro you have to Solve Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Solve Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Solve Therapeutics is a clinical-stage oncology biotech developing antibody-drug conjugates (ADCs) and radiopharmaceuticals for solid tumors, using its CloakLink hydrophilic cleavable linker system and an integrated patient-selection diagnostic platform. The company has two lead programs in Phase 1 clinical development.
Founders & leadership
Investors · 4
General Atlantic✓ confirmed by Solve TherapeuticsNew York · $10M – $1B
How we know: the company's own site · generalatlantic.com · Not right? Tell us
Decheng Capital✓ confirmed by Solve TherapeuticsMenlo Park
How we know: the company's own site · Not right? Tell us
Frequently asked questions
- What does Solve Therapeutics do?
- Solve Therapeutics is a clinical-stage oncology biotech developing antibody-drug conjugates (ADCs) and radiopharmaceuticals for solid tumors, using its CloakLink hydrophilic cleavable linker system and an integrated patient-selection diagnostic platform. The company has two lead programs in Phase 1 clinical development.
- Who are Solve Therapeutics's investors?
- Solve Therapeutics's investors include General Atlantic, Decheng Capital, Matrix Capital Management, Yosemite.